Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost
Crossref DOI link: https://doi.org/10.1186/s13023-017-0611-7
Published Online: 2017-03-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rawson, Nigel S. B.
Funding for this research was provided by:
BIOTECanada
